Plenary Session - inactive due to federal service
A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California, San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected].
- Update frequency
- every 6 days
- Average duration
- 64 minutes
- Episodes
- 397
- Years Active
- 2018 - 2025
1.17 BONUS! Interpretation of Cancer Clinical Trials
This BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health & Science University on October 5 and October 12, 2018. The talk is on how to interpret can…
01:18:03 |
Mon 22 Oct 2018
1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong
This BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the pa…
00:55:50 |
Wed 17 Oct 2018
1.15 Minimally Effective Treatments, CheckMate 331, and Dr. Adam Obley on Low-Value Healthcare
In this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the f…
01:18:22 |
Tue 16 Oct 2018
1.14 BONUS! Immunotherapy in Desperation and the Pennington Lecture: Myths of Medicine and Marketing
This BONUS episode is the recording of the 22nd annual Pennington Lecture given at Oregon Health & Science University on September 21, 2018. The lecture is on seven myths of medicine and marketing. B…
00:56:32 |
Fri 12 Oct 2018
1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu
Listen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical e…
01:37:06 |
Mon 08 Oct 2018
1.12 BONUS! Evidence-Based Medicine Has Been Hijacked in Oncology
This BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-ba…
00:37:00 |
Wed 03 Oct 2018
1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali
We discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follo…
01:48:39 |
Tue 02 Oct 2018
1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet
Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Perc…
01:12:40 |
Tue 25 Sep 2018
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric can…
00:33:41 |
Thu 20 Sep 2018
1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds
In this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-…
01:02:32 |
Fri 14 Sep 2018
1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola
In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview card…
01:02:43 |
Tue 11 Sep 2018
1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority
In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingst…
01:22:04 |
Fri 07 Sep 2018
1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity
In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-b…
01:00:56 |
Wed 05 Sep 2018
1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser
This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.
00:56:53 |
Thu 30 Aug 2018
1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross
We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA appro…
01:06:02 |
Tue 21 Aug 2018
1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar
In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.
00:35:16 |
Thu 16 Aug 2018
1.01: Introduction and Dr. Adam Obley
Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and b…
00:47:25 |
Tue 14 Aug 2018
Disclaimer: The podcast and artwork embedded on this page are the property of Vinay Prasad, MD MPH ([email protected]). This content is not affiliated with or endorsed by eachpod.com.